New diabetes shot shows promise in Mid-Stage trial
NCT ID NCT07163624
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 27 times
Summary
This study tests an investigational drug called UBT251 in 211 adults with type 2 diabetes who are already on metformin. The goal is to see if the drug can lower blood sugar levels over 24 weeks and to find the best dose for future studies. Participants receive either UBT251, a placebo, or an active comparator injection. The main measure is change in HbA1c, a key blood sugar marker.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS (T2DM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The United Bio-Technology (Hengqin) Co., Ltd.
Zhuhai, Guangdong, 519000, China
Conditions
Explore the condition pages connected to this study.